Novo Nordisk
NVO
530 hedge funds and large institutions have $10.4B invested in Novo Nordisk in 2016 Q2 according to their latest regulatory filings, with 49 funds opening new positions, 158 increasing their positions, 218 reducing their positions, and 47 closing their positions.
4% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 47
2% more call options, than puts
Call options by funds: $24.1M | Put options by funds: $23.6M
0.08% more ownership
Funds ownership: 19.07% → 19.15% (+0.08%)
3% less capital invested
Capital invested by funds: $10.7B → $10.4B (-$298M)
1% less funds holding
Funds holding: 536 → 530 (-6)
4% less funds holding in top 10
Funds holding in top 10: 25 → 24 (-1)
28% less repeat investments, than reductions
Existing positions increased: 158 | Existing positions reduced: 218
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$134M |
| 2 |
Wells Fargo
San Francisco,
California
|
+$86.4M |
| 3 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$38.7M |
| 4 |
WCM Investment Management
Laguna Beach,
California
|
+$24.7M |
| 5 |
Morgan Stanley
New York
|
+$16.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$150M |
| 2 |
JSP
Jackson Square Partners
Larkspur,
California
|
-$129M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$53.1M |
| 4 |
Capital International Investors
Los Angeles,
California
|
-$50.2M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$21.9M |
NVO Hedge Fund Activity: Q2 2016 in Review
530 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk (NVO) for Q2 2016, worth a combined $10.4B — down 2.8% from $10.7B a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new NVO positions and 47 closed out — a net gain of 2 holders — while 158 added to existing stakes and 218 trimmed.
The largest buyer was Jennison Associates, adding an estimated $134M. The largest seller was Arrowstreet Capital, cutting an estimated $150M.
- 530 institutional investors held Novo Nordisk (NVO) as of Q2 2016, down from 536 in Q1 2016.
- Funds reported $10.4B of Novo Nordisk stock for Q2 2016, down 2.8% quarter-over-quarter.
- 49 funds opened new Novo Nordisk positions in Q2 2016 and 47 closed out, a net change of +2 holders.
- The largest Novo Nordisk buyer in Q2 2016 was Jennison Associates, an estimated $134M added.
- The largest Novo Nordisk seller in Q2 2016 was Arrowstreet Capital, an estimated $150M sold.
Based on aggregated 13F filings for Q2 2016.